Key Takeaways
- Pricing windfall drove the quarter: API realizations jumped on war-driven supply tightness, pushing revenue growth well ahead of the modest ~3.5% volume growth and lifting EBITDA margin above 14%.
- Sayakha ramp is the margin story: Methylamine utilization hit ~65% and captive intermediate consumption is set to rise sharply from Q2, a shift management expects to add roughly 1% to gross contribution at peak, conditional on pricing settling.
- Salicylic acid remains a deliberate drag: Production was kept to just 67 tons for the quarter while cost-reduction equipment was installed; Chinese players have since slashed pricing to drive competition out, and the anti-dumping duty case is now delayed by roughly one more year.
- Regulated-markets pivot is funded but not yet earning: USFDA and European approvals are in hand for key products, a fresh quasi-greenfield USFDA block is planned, and business development has begun, but the current sales base does not yet reflect the margin premium those markets should eventually deliver.
- What to watch next quarter: Whether the promised jump in captive consumption materializes, the trajectory of API realizations as war-driven spikes ease, and any volume recovery as downstream inventory normalizes.
API Pricing & Demand Dynamics
- War-driven price spike: API realizations improved significantly as the U.S.-Iran conflict tightened availability in certain markets and pushed customers to prioritize supply reliability over price. The sharpest move came around March and April, and while prices have eased slowly since, they remain elevated because the war restarted.
- Volume lagged price: Aggregate volume growth was only ~3.5% in Q1, with the majority of revenue growth coming from price. Sharp raw material cost increases caused formulation purchasers to keep inventory to a minimum, compressing quantity sales.
- Demand split by geography: Export demand is expected to hold up well; domestic demand faces pressure in very high price scenarios, especially for antibiotics and antidiarrheals, a pattern management observed during a similar cycle 3–4 years back.
- Volume recovery bet: Management hopes volume growth will be much better than the June quarter, reasoning that once prices stay high for longer, inventory levels further down the value chain will deplete and demand should return.
Adhish Patil: "The thing is in the broad scenario, we just thought a month back that everything streamlined and everything will come back to normal. But again, things are quite volatile as of now to say anything. ... for us, frankly speaking, even if prices are lower, but if they are stable, then we can definitely make handsome margins."
Sayakha Ramp & Margin Bridge
- Utilization milestone: The Sayakha methylamine plant reached ~65% utilization in Q1, the first quarter above 60%, contributing to the EBITDA margin improvement.
- Captive consumption inflection: In the June quarter, 60–70% of intermediates were still procured externally; that percentage has fallen drastically in the current September quarter, and management hopes 80–90% captive consumption by the December quarter, keeping roughly 10% external for diversification.
- Gross margin tailwind: Captive consumption from Sayakha is expected to add roughly 1% in gross contribution at peak levels. Combined with better utilization, this could drive a 200 basis point improvement, though management cautioned that whether the 200 basis points will come depends on whether ammonia shortage-driven price spikes settle down.
- Phase 2 capex efficiency: The next phase of brownfield capex at Sayakha and G61 in Tarapur is expected to deliver asset turns of 3x–4x because common facilities such as ETPs are already in place.
- Short-term margin caution: If API realizations ease as war-driven pricing comes down, the ~14% EBITDA margin seen in Q1 may soften; however, volume growth should pick up when pricing declines.
Adhish Patil: "So 14% is quite doable. We are almost there. Now once the utilization of the two main greenfield projects what we have put up once that improves, then definitely 15% should be very easy. Once the Salicylic acid plant comes on track, then that drag will reduce on the overall P&L."
Salicylic Acid: The Deliberate Drag
- Production deliberately curtailed: Only 67 tons of salicylic acid were produced in the entire quarter because the company was waiting for equipment installation aimed at reducing raw material cost and improving effluent quality. That equipment is now installed.
- Chinese pricing assault: After Aarti Drugs launched its capacity, Chinese players drastically dropped salicylic acid pricing to drive competition out, making downstream salicylates more profitable than salicylic acid itself.
- Derivatives plant commissioned: A multipurpose plant for methyl salicylate and other salicylates with capacity of roughly 350–400 tons per month has been commissioned; trial batches of 5–10 tons have begun. The strategy is to produce salicylic acid and convert it into derivatives to reduce losses and try to achieve breakeven at that location.
- Anti-dumping duty delayed: The government asked for the injury period to be extended by one more year; management expects a wait of most probably one more year but is "pretty much sure" the duty will come.
Adhish Patil: "But then after we launched the capacity, Chinese players, they drastically dropped the pricing of salicylic acid, mainly to drive the competition out. That is the main purpose."
Metformin: Capacity, Approvals & Market Access
- Capacity scale-up underway: Current plan is to expand Metformin capacity from 1,400 tons per month to roughly 2,200 tons per month, with the Sarigam facility scaling to ~1,700 tons and an additional ~500–550 tons per month in a dedicated USFDA block at the same location.
- USFDA timeline: The fresh ~500+ tons per month USFDA capacity will take roughly 10–12 months to construct; immediately upon completion, the company will file for USFDA inspection with help from a customer, meaning API supplies to the U.S. can begin at the earliest after 12 months.
- European unlock via USFDA: Many European Metformin clients also operate in the U.S. market and require a supplier that holds both European and USFDA approvals. Management views the USFDA filing as the key that opens not only the U.S. but also the large European market.
- Demand tailwind: Management expects Metformin demand to grow quite significantly as more approvals are obtained.
Adhish Patil: "The key challenge what we faced so far is that many of the European clients of Metformin are also operating in the US market, so they need a supplier who is both European as well as USFDA approved. And that is the main reason why we are going in for USFDA approval because that will open up not only the US market but also the huge European markets for us as well."
Regulated Markets & Formulations Build-Out
- Approvals in hand: USFDA approval obtained for oncology; European approval obtained for oral solid dosage; European-CEP approvals secured for 9 products. Filings for regulated markets are ongoing.
- USFDA plant expansion planned: The existing USFDA plant has 2 main production lines and 1 small product line with 4–5 active products supplying EU markets. A fresh quasi-greenfield project on an adjacent plot will add 3 more multipurpose production lines of roughly 10 tons per month each, more than doubling existing capacity. Management expects the current plant to fall short within a year because products are large in tonnage.
- Baddi brownfield expansion: A brownfield expansion on an adjacent land parcel is progressing as planned and is expected to nearly double oral solid dosage manufacturing capacity once completed.
- Profitability still in development phase: Current sales do not yet reflect the margin premium that regulated markets should deliver; the business is still in the business development phase with samples sent to U.S. customers. As the regulated-market pie becomes meaningful, it will be meaningfully reflected in overall EBITDA margins.
- Cost-structure shift: Some products are being shifted to a bigger WHO/GMP plant that will be transformed into an EDQM-approved plant, which management expects will lower cost structure, increase pricing, expand margin, and bring more volumes.
Specialty Chemicals & Competitive Position
- Specialty Chemicals breakout quarter: Q1 sales reached roughly ₹82 crores with 149% growth, driven by the new Sayakha facility coming online. Management expects this quarterly performance to repeat for the next 3 quarters and will try to improve it further.
- API competitive stability: Management stated that competing with China was never an issue for its product line and that the API business, given the product profile the company operates in, is quite stable and not threatened by Chinese competition.
- Volume growth target: The company is well poised for 10% to 15% volume growth over the next two years; the only challenge is how fast the salicylic acid and derivatives part gets streamlined. Even if salicylic acid derivatives do not pick up, 10% volume growth should still be doable.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Captive consumption ramp | 80–90% captive intermediate consumption at Sayakha (vs 60–70% procured externally in Q1) | December quarter |
| Gross margin improvement | Captive consumption to add roughly 1% in gross contribution | At peak utilization |
| Metformin USFDA capacity | Fresh ~500+ tons per month block constructed; file for USFDA inspection | 10–12 months to construct; supplies earliest after 12 months |
| Specialty Chemicals run rate | Q1 performance (~₹82 crores) to repeat | Next 3 quarters |
| Anti-dumping duty on salicylic acid | Government decision expected | Most probably 1 more year |
| Volume growth | 10% to 15% volume growth | Over next two years |
| EBITDA margin | 15% achievable once greenfield utilization improves and salicylic acid drag reduces | No specific date; conditional on utilization and pricing stability |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated revenue | ₹703.6 cr, +19% YoY |
| Standalone revenue | ₹627.6 cr, +20% YoY; 89% of consolidated revenue |
| Standalone domestic revenue | 68% of standalone revenue, +25% YoY |
| Standalone export revenue | 32% of standalone revenue, +12% YoY |
| Consolidated EBITDA | ₹96.9 cr, +30% YoY |
| Consolidated EBITDA margin | 13.8%, +120 bps YoY; crossed ~14% after write-offs of aging Capital WIP |
| Consolidated PBT | ₹69.2 cr, +35% YoY |
| Consolidated PBT margin | 9.9%, +120 bps YoY |
| Consolidated PAT | ₹50.1 cr; Q1 FY26 PAT of ₹54.0 cr included a principal tax refund of ₹15 cr, excluding which growth impact would be +29% YoY |
| Formulations segment revenue | ₹81.6 cr, +8% YoY; exports contributed ~74% |
| API therapeutic mix: antibiotic | 35.0% of total API sales |
| API therapeutic mix: antidiabetic | 18.2% of total API sales |
| API therapeutic mix: antiprotozoal | ~18.5% of total API sales |
| API therapeutic mix: anti-inflammatory | 11.9% of total API sales |
| API therapeutic mix: antifungal | 10.2% of total API sales |
| Aggregate volume growth (company level) | ~3.5% YoY, domestic and export combined |
| Aggregate price growth (company level) | ~16–17% YoY |
| Sayakha facility utilization | ~65% in Q1 FY27, up from 30–40% in Dec and Mar quarters |
| Metformin capacity utilization | Mid-80s% of ~1,400 tons per month |
| Metformin pricing movement | Up ~15–20% compared to pre-war levels |
| Specialty Chemicals sales | ~₹82 cr in Q1, +149% growth |
| Methylamine production (Sayakha) | ~3,500 tons for the June quarter, ~60 tons per day |
| Salicylic acid production | 67 tons in the June quarter; capacity of 600 tons per month at ~70% utilization |
| Captive intermediate procurement from outside | ~60–70% in June quarter; expected to drop to 10–20% by Dec quarter |